Publications by authors named "I Rojas-Marcos"
The extracellular matrix (ECM) has an important role in the development and maintenance of skeletal muscle, and several muscle diseases are associated with the dysfunction of ECM elements. MAMDC2 is a putative ECM protein and its role in cell proliferation has been investigated in certain cancer types. However, its participation in skeletal muscle physiology has not been previously studied.
View Article and Find Full Text PDFAutoantibody screening in Guillain-Barré syndrome.
J Neuroinflammation
November 2021
Background: Guillain-Barré syndrome (GBS) is an acute inflammatory neuropathy with a heterogeneous presentation. Although some evidences support the role of autoantibodies in its pathogenesis, the target antigens remain unknown in a substantial proportion of GBS patients. The objective of this study is to screen for autoantibodies targeting peripheral nerve components in Guillain-Barré syndrome.
View Article and Find Full Text PDFObjective: To study baseline serum neurofilament light chain (sNfL) levels as a prognostic biomarker in Guillain-Barré syndrome (GBS).
Methods: We measured NfL in serum (98 samples) and cerebrospinal fluid (CSF) (24 samples) of patients with GBS prospectively included in the International GBS Outcome Study (IGOS) in Spain using single-molecule array (SiMoA) and compared them with 53 healthy controls (HCs). We performed multivariable regression to analyse the association between sNfL levels and functional outcome at 1 year.
Article Synopsis
- Late onset Pompe disease (LOPD) leads to gradual weakness in skeletal and respiratory muscles, which is treated with enzyme replacement therapy (ERT) using alglucosidase alpha (rhGAA).
- In a study of 25 ERT-treated patients, 72% developed antibodies against rhGAA, but their impact on clinical progression was examined with muscle function tests, spirometry, and quantitative MRI over one year.
- Results showed that low and intermediate antibody levels did not significantly affect muscle function, breathing tests, or MRI outcomes, suggesting these antibodies may not hinder the effectiveness of the treatment.
Background: To assess management patterns and outcome in patients with glioblastoma multiforme (GBM) treated during 2008-2010 in Spain.
Methods: Retrospective analysis of clinical, therapeutic, and survival data collected through filled questionnaires from patients with histologically confirmed GBM diagnosed in 19 Spanish hospitals.
Results: We identified 834 patients (23% aged >70 years).